JO
CATX icon

John Overdeck’s Perspective Therapeutics CATX Stock Holding History

John Overdeck’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Buy
1,556,451
+552,977
+55% +$2.09M ﹤0.01% 2092
2026
Q1 		$4.18M Sell
1,003,474
-195,170
-16% -$825K ﹤0.01% 2130
2025
Q4 		$3.3M Buy
1,198,644
+678,976
+131% +$1.94M ﹤0.01% 2075
2025
Q3 		$1.78M Sell
519,668
-82,137
-14% -$299K ﹤0.01% 2208
2025
Q2 		$2.07M Sell
601,805
-12,991
-2% -$34.3K ﹤0.01% 1812
2025
Q1 		$1.31M Sell
614,796
-35,555
-5% -$107K ﹤0.01% 2012
2024
Q4 		$2.07M Buy
+650,351
New +$5.31M ﹤0.01% 1681
2021
Q2 		– Sell
-6,349
Closed -$69K – 4080
2021
Q1 		$69K Buy
+6,349
New +$95.9K ﹤0.01% 3729

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

John Overdeck's CATX Position: Q2 2026 in Review

John Overdeck increased its Perspective Therapeutics (CATX) stake by 55% in Q2 2026, buying an estimated $2.09M and bringing the position to 1,556,451 shares worth $5.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

John Overdeck first reported a position in CATX in Q1 2021 and has held it in 8 quarters since. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • John Overdeck held 1,556,451 shares of Perspective Therapeutics worth $5.31M as of Q2 2026.
  • John Overdeck bought 552,977 Perspective Therapeutics shares in Q2 2026, an estimated $2.09M.
  • Perspective Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2092 holding.
  • John Overdeck first reported a position in Perspective Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.